Journal of Practical Hepatology ›› 2021, Vol. 24 ›› Issue (6): 930-933.doi: 10.3969/j.issn.1672-5069.2021.06.041
Previous Articles Next Articles
Liang Chen, Zheng Sujun
Received:
2020-10-22
Published:
2021-11-15
Liang Chen, Zheng Sujun. Highlights of treatments for patients with Wilson's disease[J]. Journal of Practical Hepatology, 2021, 24(6): 930-933.
[1] Czlonkowska A, Litwin T, Dusek P, et al. Wilson disease. Nat Rev Dis Primers, 2018, 4(1):21. [2] Yuan XZ, Yang RM, Wang XP. Managementperspective of Wilson's disease: early diagnosis and individualized therapy. Curr Neuropharmacol, 2020[ahead of print]. [3] Gitlin JD. Wilson disease. Gastroenterology, 2003, 125(6):1868-1877. [4] European Association for Study of L. EASLclinical practice guidelines: Wilson's disease. J Hepatol, 2012, 56(3):671-685. [5] Roberts EA,Schilsky ML, American Association for Study of Liver D. Diagnosis and treatment of Wilson disease: an update. Hepatology, 2008, 47(6):2089-2111. [6] Lowette KF, Desmet K, Witters P, et al. Wilson's disease: long-term follow-up of a cohort of 24 patients treated with D-penicillamine. Eur J Gastroenterol Hepatol, 2010, 22(5):564-571. [7] Zhou X, Xiao X, Li XH, et al.A study of susceptibility-weighted imaging in patients with Wilson disease during the treatment of metal chelator. J Neurol, 2020, 267(6):1643-1650. [8] Xu SQ, Li XF, Zhu HY, et al. Clinical efficacy and safety of chelation treatment with typical penicillamine in cross combination with DMPS repeatedly for Wilson's disease. J Huazhong Univ Sci Technolog Med Sci, 2013, 33(5):743-747. [9] 任明山,杨任民, 张波, 等. 二巯丙磺钠与二巯丁二酸或青霉胺治疗肝豆状核变性的比较. 中国新药与临床杂志, 1998,6(1):3-5. [10] Wang XP, Yang RM,Ren MS, et al. Anticopper efficacy of captopril and sodium dimercaptosulphonate in patients with Wilson's disease. Funct Neurol, 2003, 18(3):149-153. [11] 李文杰, 王晓平. 肝豆状核变性治疗药物二巯丁二酸(钠). 世界临床药物, 2012, 33(9):574-576. [12] Weiss KH,Thurik F, Gotthardt DN, et al. Efficacy and safety of oral chelators in treatment of patients with Wilson disease. Clin Gastroenterol Hepatol, 2013, 11(8):1028-1035. [13] Litwin T, Dziezyc K, Karlinski M, et al. Early neurological worsening in patients with Wilson's disease. J Neurol Sci, 2015, 355(1-2):162-167. [14] Czlonkowska A, Litwin T, Karlinski M, et al. D-penicillamine versus zinc sulfate as first-line therapy for Wilson's disease. Eur J Neurol, 2014, 21(4):599-606. [15] Ranucci G, Di Dato F, Spagnuolo MI, et al. Zinc monotherapy is effective in Wilson's disease patients with mild liver disease diagnosed in childhood: a retrospective study. Orphanet J Rare Dis, 2014, 9:41. [16] Weiss KH,Gotthardt DN, Klemm D, et al. Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease. Gastroenterology, 2011, 140(4):1189-1198 e1181. [17] Roy S,Ganguly K, Pal P, et al. Influence of apolipoprotein E polymorphism on susceptibility of Wilson disease. Ann Hum Genet, 2018, 82(2):53-59. [18] Zhang S, Chen S, Li W, et al. Rescue of ATP7B function in hepatocyte-like cells from Wilson's disease induced pluripotent stem cells using gene therapy or the chaperone drug curcumin. Hum Mol Genet, 2011, 20(16):3176-3187. [19] Schilsky ML, Scheinberg IH, Sternlieb I. Liver transplantation for Wilson's disease: indications and outcome. Hepatology, 1994, 19(3):583-587. [20] Ni W, Dong QY, Zhang Y, et al. Zincmonotherapy and a low-copper diet are beneficial in patients with Wilson disease after liver transplantation. CNS Neurosci Ther, 2013, 19(11):905-907. [21] Damsgaard J, Larsen FS, Ytting H. Reversal of acute liver failure due to Wilson disease by a regimen of high-volume plasma exchange and penicillamine. Hepatology, 2019, 69(4):1835-1837. [22] Zimbrean P, Seniow J. Cognitive and psychiatric symptoms in Wilson disease. Handb Clin Neurol, 2017, 142:121-140. [23] Litwin T, Dusek P, Czlonkowska A. Symptomatic treatment of neurologic symptoms in Wilson disease. Handb Clin Neurol, 2017, 142:211-223. [24] Weiss KH,Czlonkowska A, Hedera P, et al. WTX101 - an investigational drug for the treatment of Wilson disease. Expert Opin Investig Drugs, 2018, 27(6):561-567. [25] Weiss KH,Askari FK, Czlonkowska A, et al. Bis-choline tetrathiomolybdate in patients with Wilson's disease: an open-label, multicentre, phase 2 study. Lancet Gastroenterol Hepatol, 2017, 2(12):869-876. [26] Brewer GJ,Askari F, Lorincz MT, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol, 2006, 63(4):521-527. [27] Gupta S. Cell therapy to remove excess copper in Wilson's disease. Ann N YAcad Sci, 2014, 1315:70-80. [28] Chen S, Shao C, Dong T, et al. Transplantation of ATP7B-transduced bone marrowmesenchymal stem cells decreases copper overload in rats. PLoS One, 2014, 9(11):e111425. [29] Litwin T, Dziezyc K, Czlonkowska A. Wilson disease-treatment perspectives. Ann Transl Med, 2019, 7(Suppl 2):S68. [30] 张东锋, 王煜姝, 滕军放. 骨髓间充质干细胞对肝豆状核变性合并肝纤维化肝功能的临床研究. 中国免疫学杂志, 2016, 32(2):193-196,200. [31] Roy-Chowdhury J, Schilsky ML. Gene therapy of Wilson disease: a "golden" opportunity using rAAV on the 50th anniversary of the discovery of the virus. J Hepatol, 2016, 64(2):265-267. [32] Murillo O, Moreno D,Gazquez C, et al. Liver expression of a MiniATP7B gene results in long-term restoration of copper homeostasis in a Wilson disease Model in mice. Hepatology, 2019,70(10):108-126. [33] Murillo O,Luqui DM, Gazquez C, et al. Long-term metabolic correction of Wilson's disease in a murine model by gene therapy. J Hepatol, 2016, 64(2):419-426. [34] Greig JA, Nordin JML, Smith MK, et al. A gene therapy approach to improve copper metabolism and prevent liver damage in a mouse model of Wilson disease. Hum Gene Ther Clin Dev, 2019, 30(1):29-39. [35] Kenney GE,Dassama LMK, Pandelia ME, et al. The biosynthesis of methanobactin. Science, 2018, 359(6382):1411-1416. [36] Krishnan N,Felice C, Rivera K, et al. DPM-1001 decreased copper levels and ameliorated deficits in a mouse model of Wilson's disease. Genes Dev, 2018, 32(13-14):944-952. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||